Treatment with CDDO-Im prevented HFD-induced obesity, adipogenesis, and hepatic lipid accumulation in wild-type mice, but not in NFE2L2-deficient mice [54], indicating a potential therapeutic benefit of the NFE2L2-activating molecule. Here, NFE2L2 is linked to obesity due to melanocortin 4 receptor deficiency.